Protokinetix, Inc. · OTC:PKTX
Protokinetix — Investor Presentation (June 2019)
20 slides from Protokinetix's investor presentation, June 2019
Slide 1: Harnessing Nature to Improve Health
Harnessing Nature to Improve Health
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements The information discussed in this presentation includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”)
Slide 3: OTCQB: PKTX Investor Presentation 2019
OTCQB: PKTX Investor Presentation 2019 www.protokinetix.com @ProtoKinetix
Slide 4: Company Overview
The company has a lean R&D operation with a focused platform utilizing key partnerships with Academic Brain Trusts and leading Pharmaceutical CROs to support commercialization. We are continuing to develop a family of nature-inspired PKTX glycopeptides to address medical market needs. The comp
Slide 5: Key Market Indications
Opthamology (Eyes) Dermatology (Skin) PKTX Key Market Indications Transplant Support Biological Manufacturing (Cells & Organs) (mAB production)
Slide 6: PKTX Addressable Market Values
Opthamology (Eyes) Dermatology (Skin) $4-6 Billion $44-82 Billion Dry Eye Disease Skin Care Market Market with a (OTC & Rx) with a CAGR 7% CAGR 8-11% PKTX Transplant Support Biological Manufacturing Addressable (Cells & Organs) (mAB production) Market Values $73-127 Billion $285-480 Billion Organ Tr
Slide 7: Lead Compound
PKX-001 is a patent protected small peptide molecule, that is produced entirely by synthetic chemistry methods. PKTX PKX-001 has demonstrated therapeutic efficacy via anti- inflammatory, anti-oxidant, anti-cold injury, & UV-protection. PKX-001 has a therapeutic range of 0.1 to 5mg/ml; is highl
Slide 8: Market Indication: Dry Eye Disease
Dry eye disease impacts women more than men & has double digit % growth in emerging markets & in orphan diseases. • The population affected is 7% (20% over 75yr) where nearly 17% of population is >65yr by 2050. • Early market positioning in OTC dry eye disease and veterinary treatment for keratoconj
Slide 9: Market Indications: UV Protection for Skin
Whether applied before or after UV ray exposure, PKX-001 can both protect and rescue skin from UV damage. * PKTX ** Market Indications Reference: PKTX Investigator’s Brochure Ed. 1.0
Slide 10: Protecting Islet Cell Transplants for Type-1 Diabetes
Enhancing the Curative Potential for Type-1 Diabetes by Protecting Islet Cell Transplants. PKTX Market Indication Reference: Diabetes. 2016 Feb;65(2):451-62 & PKTX Investigator’s Brochure Ed. 1.0
Slide 11: Maintenance of Stem Cell Marker OCT4
Maintenance of Stem Cell Marker OCT4 PKC-001 PKTX Market Indication The bottom line for biological manufacturers could Reference: PKTX Investigator’s Brochure Ed. 1.0 be a 3-5 fold gain in value production.
Slide 12: Clinical Academic Brain Trusts
Dr. James Shapiro, Alberta Diabetes Institute, Founder of the Edmonton Protocol for T1D Dr. Gregory Evans, Julia Levy Chair in Ophthalmology PKTX Dr. Mike Williams, AbLab, UBC Dr. Kelly McNagny, CBR, UBC Clinical Academic Dr. Boris Gala-Lopez, Brain Trusts Dalhousie Transplantation Lab &
Slide 13: Pharmaceutical Partners
AmbioPharma (GCP Production & IP Partner) BRI & Nelson Laboratories (Quality Control Analytical) PKTX ITR Laboratories (Safety Pharmacology Testing) Pharmaceutical Partners Iotron (GCP Medical Sterilization for Human Trials) TBA - (Special Product Formulations & Packaging), (GMP eye testin
Slide 14: Lean R&D Company Go-To-Market Strategy
Perspective on the Lean R&D Company Go-To-Market Strategy Infrastructure Human Capital Leveraged Funding Ideation to Minimal Viable Investors Market Products & Proof of Concept Passive Marketing • OTC & Rx Eye Drops – Investigator Initiated Clinical Trials Arctic Tears Stable $$$$$$ • OT
Slide 15: Near Term Objectives & Milestones
Near term Objectives & Milestones (Next 12-24 Months) Identify and secure specialized formulations CRO partner(s) familiar with meeting OTC & Rx regulatory requirements to position for market entry and revenue generation. Determine suitability and partner with a Brain Trust (OVC or PEI) for earl
Slide 16: Investment Highlight
Exclusive secured composition of matter IP and trade secret synthetic chemistry manufacturing process that is rapidly scalable. A capacity for expanded patent securities through pipeline product formulations, in/out licensing, and registrations for orphan disease designations with the FDA. Wel
Slide 17: Leadership
Clarence E. Smith (55yr), CEO & President – a serial entrepreneur with 38years of expertise of executive business management from inception to development, acquisitions, and mergers. Serving on the Board of Directors for 5-years and currently an activist owner collecting $1/yr salary and major share
Slide 18: Stock Snapshot
$37 Million Mkt Cap $0.15/share PKTX Stock +45% SMA200 Snapshot (June 1, 2019) 28% Insider Ownership Reference: Wallmine.com US market reporting YTD values rounded to 1 decimal, June 1, 2019
Slide 19: Contact Information
PKTX Contact Information ProtoKinetix Inc. 412 Mulberry St. Marietta, Ohio, 45750 http://www.protokinetix.com/ @ProtoKinetix
Slide 20: ProtoKinetix Inc. Cell Survival Solutions
ProtoKinetix Inc. Cell Survival Solutions OTC: PKTX @ProtoKinetix www.protokinetix.com Confidentiality Statement The information contained herein is confidential and the proprietary property of ProtoKinetix, Inc. Any unauthorized use or disclosure of such information without the prior written author